Study title: Wexler LH et al Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors Cancer. 1996 Aug 15;78(4):901-11. Erratum in: Cancer 1997 Feb 15;79(4):867 Wexler LH et al Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors Cancer. 1996 Aug 15;78(4):901-11. Erratum in: Cancer 1997 Feb 15;79(4):867
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Neoplasms | |||||
| Brands: Please see report, Please see report, Please see report, Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: ETOPOSIDE AND IFOSFAMIDE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |